ENTA Stock Catalyst: Enanta Pharmaceuticals Inc. Reported Topline Data from Phase 2b Study of Zelicapavir

Sep 29, 2025 · 4:00am ET

The study evaluated the efficacy and safety of Zelicapavir, an RSV pill.

Max move

+65.2%

High of day $15.88

Sparker timei

4:00am ET

ENTA · Sep 29, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Enanta Pharmaceuticals Inc. (ENTA) announced topline data from a Phase 2b study assessing Zelicapavir, an RSV pill, in outpatient adults with acute RSV infection. The study aimed to evaluate both the efficacy and safety of the drug.

No specific amounts or filings were disclosed in the announcement. The company did not provide comparative data for the study results.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ENTA sparks.

Download Sniper App →

Catch the next ENTA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →